about
DNA and the chromosome - varied targets for chemotherapyProdrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy)Redox activation of metal-based prodrugs as a strategy for drug deliveryRecent trends in targeted anticancer prodrug and conjugate design.Localized in vivo activation of a photoactivatable doxorubicin prodrug in deep tumor tissue.Characterization of aziridinylbenzoquinone DNA cross-links by liquid chromatography-infrared multiphoton dissociation-mass spectrometry.Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidaseExtraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue.Molecular imaging of gliomas with PET: opportunities and limitations.A novel Doxorubicin prodrug with controllable photolysis activation for cancer chemotherapyPhotoactivated chemotherapy (PACT): the potential of excited-state d-block metals in medicine.Tumor xenograft uptake of a pyrrole-imidazole (Py-Im) polyamide varies as a function of cell line grafted.Overview of the clinical efficacy of investigational anticancer drugs.Applications of molecular imaging.Targeted expression of suicide gene by tissue-specific promoter and microRNA regulation for cancer gene therapyProdrugs for improving tumor targetability and efficiency.Toward a high-throughput screening platform for directed evolution of enzymes that activate genotoxic prodrugs.Tumor-activated prodrugs--a new approach to cancer therapy.Chemical approaches to the discovery and development of cancer therapies.Tumor-specific expression of shVEGF and suicide gene as a novel strategy for esophageal cancer therapy.Tumour endoproteases: the cutting edge of cancer drug delivery?Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug mono-therapy of cancer.Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.PET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development.The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrugAnticancer activity of metal complexes: involvement of redox processes.Protein-polymer nanoreactors for medical applications.Hypoxic tumor microenvironment: Opportunities to develop targeted therapies.A highly sensitive long-wavelength fluorescence probe for nitroreductase and hypoxia: selective detection and quantification.Targeted delivery of a phosphopeptide prodrug inhibits the proliferation of a human glioma cell line.Preliminary studies with a new hypoxia-selective cytotoxin, KS119W, in vitro and in vivo.Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug.Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model.Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma.ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage.Ruthenium dihydroxybipyridine complexes are tumor activated prodrugs due to low pH and blue light induced ligand releaseUsefulness of positron emission tomographic studies for gliomas.Preferential DNA cleavage under anaerobic conditions by a DNA-binding ruthenium dimerA combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity.Use of the EGP-2/Ep-CAM promoter for targeted expression of heterologous genes in carcinoma derived cell lines.
P2860
Q24792540-4535104A-94A1-4DEB-8C10-561487653ED3Q24792836-8119104C-6721-4485-9750-6FF0ECFAA15EQ27025736-DC6A8544-3786-49B7-A2B6-8ADB5E714349Q33573762-4E8B8610-5744-4D7F-A198-C70BFEF40A4DQ33812832-B9ACC665-71BD-4724-B3FF-69EAF300F160Q33936414-9AB28073-30A6-46D8-B06B-8235E3F85381Q33936498-57FADB2C-032D-4A11-A9A8-285BEE2146DDQ33946444-7E21557C-2FAF-449D-AC19-6189FB093800Q33961188-70328A8E-57B4-4D81-8400-0B43061E427FQ34044370-B8FA64D4-C42F-4390-98FC-74AEBA6029D5Q34105908-520150AE-BD96-46D1-B2D6-D9BFF7B650E4Q34394131-9DC895AC-2BB5-4422-A339-694A2745CE8FQ35067125-0B4925DD-4167-431C-BDC9-898378AB12C0Q35082412-D2DCAFE9-FCB2-4C08-B5E9-25E86B4FFBCDQ35082459-D83E559E-2B73-46C4-B552-454615707E29Q35095165-981668DF-2794-427B-A5F7-7E5D3FF44917Q35201410-0E099546-DAD5-4AC6-98D9-ECFB6F580255Q35964429-E19C4022-E4D9-4B8C-BAE4-451781B4BB37Q36085630-1F123DEE-E7AD-4567-BDFB-6485147F4EBFQ37012358-6E7AA8D7-E79E-4B85-98E1-8DB0A8F35046Q37060284-BC440FE1-73CD-4DD0-A363-FDDED308A1E4Q37083440-53DF67D6-259F-4BCA-9B5D-732BFEDA805BQ37283967-6F593332-B481-4693-896C-F464A7F122D2Q37374442-8EB3B4F7-3C5F-49BC-8DB5-7F5D216CB270Q37565506-4F047942-115A-4899-BE54-9682AB0D2857Q37833099-2BA66476-594A-4B4A-8FEF-571444AAECFCQ37956493-3653A519-13D9-476E-AB25-33B306EB8260Q38824983-5E5E8798-2986-440A-ABBD-3382DE2E36EEQ39079811-9A215F35-ADF7-448E-ACCB-CADFC36C71A6Q39116826-9A7B6328-1404-4D21-96B9-C318A719759AQ39302741-51A3EEF5-9624-4AD7-B527-3B0C864C2127Q39599536-CBB819AA-5A7F-47C2-B251-AFA95787D0F8Q40397931-47CE8A12-9F57-4E4A-A211-71E1F88A3038Q40432870-32DE5B7B-DDFD-4A7C-9DCC-1865B4B01A56Q41815659-841A787B-4195-4DEA-9E8D-493680073460Q41853096-0491CEF4-6684-48F3-9557-93149610906CQ41965733-FEEAC712-0E09-477C-8C03-D76B0B104F28Q42137317-57EC8C48-5E12-4C3A-ADE4-9AAA31BC6563Q44502775-DC1A4230-E157-42C5-AAB8-052BEC9B7409Q44970730-9836EBD8-413E-4814-800F-F43832E5ED93
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Prodrug strategies in cancer therapy.
@ast
Prodrug strategies in cancer therapy.
@en
Prodrug strategies in cancer therapy.
@nl
type
label
Prodrug strategies in cancer therapy.
@ast
Prodrug strategies in cancer therapy.
@en
Prodrug strategies in cancer therapy.
@nl
prefLabel
Prodrug strategies in cancer therapy.
@ast
Prodrug strategies in cancer therapy.
@en
Prodrug strategies in cancer therapy.
@nl
P1476
Prodrug strategies in cancer therapy.
@en
P2093
P304
P356
10.1016/S0223-5234(01)01253-3
P577
2001-07-01T00:00:00Z